Recently, Leecan Pharmaceutical successfully obtained the production approval for its inhaled beclomethasone dipropionate suspension (GYZZ H20265778), becoming the third pharmaceutical company in China to receive approval for this product. This marks another significant achievement in the company's inhaled formulation product pipeline.

This product, which is independently developed, produced, and commercialized by Leecan Pharmaceutical, represents another key achievement in the company's deep exploration of the high-end inhalation formulation sector. It further strengthens the product matrix in the respiratory field and brings a new high-quality domestic nebulization treatment option to patients with respiratory diseases in China.

Inhaled beclomethasone dipropionate suspension is a potent inhaled glucocorticoid that exerts its effect locally and precisely in the airway after nebulization. It possesses strong anti-inflammatory and anti-allergic properties, effectively inhibiting airway inflammatory exudation, reducing bronchial mucosal edema, and alleviating airway spasm. Clinically, it is primarily used for the prevention and long-term maintenance treatment of bronchial asthma. It can also be used for the intervention treatment of chronic obstructive pulmonary disease accompanied by wheezing symptoms. It is suitable for both adults and children, offering a broad range of clinical application scenarios.

Since its inception, Leecan Pharmaceutical has always adhered to its original aspiration of "serving the country with technology and giving back to society", and has been committed to the development of high-end complex and innovative preparations. Being the third enterprise in China to receive approval this time fully demonstrates that the company has achieved domestic first-class R&D and industrialization capabilities in core areas such as inhalation suspension particle size control, formulation process, and delivery technology.

Moving forward, Leecan Pharmaceutical will strictly adhere to the registered and approved process and GMP quality standards for commercial production. We will maintain strict quality control to ensure stable and safe product quality, striving to bring the product to market as soon as possible and benefit a wide range of patients. Licheng Pharmaceutical will leverage the launch of this product as an opportunity to continuously enrich our product pipeline across multiple fields, and give back to society with our craftsmanship and quality medicines, safeguarding the health of our citizens!